SLEEP DISORDERS IN NEUROLOGICAL PRACTICE: A ROLE OF MELATONIN IN THERAPY FOR PRIMARY SLEEP AND AWAKENING DISORDERS IN PATIENTS WITH PARKINSON’S DISEASE
https://doi.org/10.17650/1818-8338-2013-1-70-75
Abstract
Sleep and awakening disorders are almost obligate manifestations of Parkinson’s disease. Primary sleep and awakening disorders in Parkinson’s
disease are associated with the degeneration of serotoninergic neurons in the dorsal raphe nucleus and cholinergic neurons in the pedunculopontine nucleus. Impaired awakening maintenance with the development of hypersomnia may result from neuron degeneration in the locus coeruleus or pedunculopontine nucleus. A certain role may be played by the pathological basal ganglionic pulsation caused by striatal dopamine deficiency, which goes to both the thalamic reticular nucleus and pedunculopontine nucleus, as well as by dysfunction of the mesocortical dopaminergic pathways involved in sleep-wake cycle regulation. Synthetic melatonin (Melaxen) is one of the effective medications for the treatment of sleep disorders in Parkinson’s disease. The drug normalizes circadian rhythms and has a hypnotic effect although it is in the usual sense not a soporific agent. Melaxen has a minimum of side effects and is well tolerated by patients from different age groups.
About the Authors
N. V. Fedorova
Russian Medical Academy of Postgraduate Education, Ministry of Health of Russia
Center of Extrapyramidal Diseases, Ministry of Health of Russia
Russian Federation
Department of Neurology
Russian Federation
Department of Neurology
A. V. Nikitina
Russian Medical Academy of Postgraduate Education, Ministry of Health of Russia
Center of Extrapyramidal Diseases, Ministry of Health of Russia
Russian Federation
Department of Neurology
Russian Federation
Department of Neurology
Ye. N. Gubanova
Russian Medical Academy of Postgraduate Education, Ministry of Health of Russia
Center of Extrapyramidal Diseases, Ministry of Health of Russia
Russian Federation
Department of Neurology
Russian Federation
Department of Neurology
References
1. Foley D.J., Vitiello M.V., Bliwise D.L. et al. Frequent napping’s associated with excessive daytime sleepiness, depression, pain and nocturia in older adult. Am J Geriatr Psychiatry 2007;15(4):344–50.
2. Foley D.J., Monjan A.A., Brown S.L. et al. Sleep complaints among elderly persons an epidemiologic study of three communities. Sleep 1995;18(6):425–32.
3. Kripke D.F., Garfinkel L., Wingard D.L. et al. Mortality associated with sleep duration and insomnia. Arch Gen Psychiatry 2002;59(2):131–6.
4. Reid K.J., Marinovick Z., Finkel S. et al. Sleep: а marker of physical and mental health in the elderly. Am J Geriatr Psychiatry 2006;14(10):860–6.
5. Josshi S. Non-pharmacological therapy for insomnia in the elderly. Clin Geriatr Med 2008;24(1):107–19.
6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed.
7. Washington, DC: American Psychiatric Association, 1997.
8. Martin J., Shochat T., Ancoli-Israel S. Assessment and treatment of sleep disturbances in older adults. Clin Psychol Rev 2000;20(6):783–805.
9. Zee P., Bloom H.G. Understanding and resolving insomnia in the elderly. Geriatrics 2006;61:1–12.
10. Friedman J.H., Chou K.L. Sleep and fatigue in Parkinson's disease. Parkinsonism Relat Disord 2004;10(Suppl 1):27–35.
11. Lees A.J., Blackburn N.A., Campbell V.L. The nighttime problems of Parkinson’s disease. Clin Neuropharmacol 1988;11(6):512–9.
12. Kaynak D., Kiziltan G., Kaynak H. et al. Sleep and sleepiness in patients with Parkinson’s disease before and after dopaminergic treatment. Eur J Neurol 2005;12(3):199–207.
13. Monderer R., Thorpy M. Sleep disorders and daytime sleepiness in Parkinson’s disease. Curr Neurol Neurosci Rep 2009;9(2):173–80.
14. Boeve B.F., Silber M.H., Saper C.B. et al. Pathophysiology of REM sleep behavior disorder and relevance to neurodegenerative disease. Brain 2007;130(Pt 11):770–88.
15. Braak H., Del Tredici K., Rub U. et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003;24(2):197–211.
16. Scaglione C., Vignatelli L., Plazzi G. et al. REM sleep behavior disorder in Parkinson’s disease: a questionnaire-based study. Neurol Sci 2005;25(6):316–21.
17. Buysee D.J., Reynolds C.F. 3rd, Monk T.H. et al. The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28(2):193–213.
18. Chaudhury K.R., Pal S., DiMarco A. et al. Parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson’s disease. J Neurol Neurosurg Psychiatry
19. ;73(6):629–35.
20. Lee K.A. Self-reported sleep disturbances in employed women. Sleep 1992;15(6):493–8.
21. Johns M.W. Sleepiness in different situations measured by the Epworth sleepiness scale. Sleep 1994;17(8):703–10.
22. Akerstedt T., Gillberg M. Subjective and objective sleepiness in the active individual. Int Neurosci 1990;52(1–2):29–37.
23. Marinus J., Visser M., van Hilten J.J. et al. Assessment of sleep and sleepiness in Parkinson’s disease. Sleep 2003;26(8):1049–54.
24. Левин Я.И., Ковров Г.В. Некоторые современные подходы к терапии инсомнии. Леч врач 2003;(4):18–32.
25. Wilson J.F. In the clinic. Insomnia. Ann Intern Med 2008;148(1):ITC13-1–ITC13-16.
26. Ianas O., Olinescu R., Badescu I. Melatonin involvement in oxidative processes. Еndocrinologie 1991;29(3–4):147–53.
27. Reiter R.J., Robinson J. Melatonin. New York: Bantam books, 1995.
28. Van Someren E.J. Circadian and sleep disturbances in the elderly. Exp Gerontol 2000;35(9–10):1229–37.
29. Ruzsas C., Mess B. Melatonin and aging. A brief survey. Neuro Endocrinol Lett 2000;21(1):17–23.
30. Holliman B.J., Chyka P.A. Problems in assessment of acute melatonin overdose. South Med J 1997;90(4):451–3.
31. Dowling G.A., Mastick J., Colling E. et al. Melatonin for sleep disturbances in Parkinson’s disease. Sleep Med 2005;6(5):459–66.
32. Литвиненко И.В., Красаков И.В., Тихомирова О.В. Расстройства сна при неосложненной деменцией болезни Паркинсона: результаты контролируемого сравнительного исследования
33. применения мелатонина и клоназепама. Журн неврол и психиатр 2012;(12):26–30.
Review
For citations:
Fedorova N.V., Nikitina A.V., Gubanova Ye.N. SLEEP DISORDERS IN NEUROLOGICAL PRACTICE: A ROLE OF MELATONIN IN THERAPY FOR PRIMARY SLEEP AND AWAKENING DISORDERS IN PATIENTS WITH PARKINSON’S DISEASE. The Clinician. 2013;7(1):70-75. (In Russ.) https://doi.org/10.17650/1818-8338-2013-1-70-75
Views:
933
Email this article 